Evidence map›Paper›PMID 30124977›Full record

ArticleThe Journal of infectious diseases2018

The Damage-Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases.

Liise-Anne Pirofski, Arturo Casadevall

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Immunomodulation in the Treatment of Disseminated Coccidioidomycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Type-2 immune skewing in patients with disseminated coccidioidomycosis.medRxiv : the preprint server for health sciences · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Role ofPathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Liise-Anne PirofskiDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Arturo CasadevallDepartment of Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland.
Johns Hopkins University · USMontefiore Medical Center · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
PROTECTIVE ANTIBODIES FOR CRYPTOCOCCAL INFECTIONSR01AI033774 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1994 to 2014
$5.6M
Molecular Characterization of C. neoformans AntibodiesR37AI033142 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2007 to 2016
$3.9M
B cell subsets and immunity to cryptococcosisR01AI097096 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2012 to 2016
$2.7M
Effects of aging and HIV infection on the response to pneumococcal vaccineR01AG045044 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2014 to 2018
$2.5M
Antibody therapy for pneumococcal diseaseR01AI123654 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PIROFSKI, LIISE-ANNE · 2017 to 2021
$2.1M
NHLBI NIH HHS R01 HL059842NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI033774NIAID NIH HHS R01 AI052733NIAID NIH HHS R01 AI097096NIAID NIH HHS R01 AI123654NIAID NIH HHS R37 AI033142NIA NIH HHS R01 AG045044
6 · The paper itself

Abstract

The Damage-Response Framework (DRF) is a powerful tool to inform research in infectious diseases. It can integrate clinical observation with microbiology and immunology to incorporate the role of the host response into the outcome of microbial pathogenesis. Although the role that microbial factors may play in the pathogenesis of infectious diseases is well recognized, the DRF brings the indispensable role of the host response to the fore. For example, inflammation may induce microbial control, but it can also produce host damage. On the other hand, insufficient inflammation may fail to induce sufficient microbial control. Each scenario may lead to the diagnosis of an infectious disease. Given the central role that the host response plays in the pathogenesis of infectious diseases, new strategies for treatment need to consider the nature of the host response as well as microbial factors.

Indexed as

Host-Pathogen InteractionsPhysiciansResearch PersonnelAllergy and ImmunologyCommunicable DiseasesHumansInflammationMicrobiology

Identifiers

PMID30124977
PMCPMC6093430
OpenAlexW2886981018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.